Antimicrobial resistance among imipenem-non-susceptible Escherichia coli and Klebsiella pneumoniae isolates, with an emphasis on novel β-lactam/β-lactamase inhibitor combinations and tetracycline derivatives: The Taiwan surveillance of antimicrobial resistance program, 2020–2022

作者：Yu-Lin Lee, Chun-Eng Liu, W. Wang, Mei-Chen Tan, Peijing Chen, Yih‐Ru Shiau, Huiying Wang, Jui‐Fen Lai, I‐Wen Huang, Ya-Sung Yang, Shu‐Chen Kuo · 发表于：Journal of Microbiology Immunology and Infection · 年份：2025 · DOI：10.1016/j.jmii.2025.01.006 · 被引用次数：9 · 研究领域：Antibiotic Resistance in Bacteria、Antibiotics Pharmacokinetics and Efficacy、Antibiotic Use and Resistance

To determine susceptibility of imipenem-non-susceptible Escherichia coli (INS-EC) and Klebsiella pneumoniae (INS-KP) isolates collected during 2020–2022 through a national surveillance program in Taiwan to novel antibiotics, and to compare the results with those obtained during 2012–2018. Minimum inhibitory concentrations were determined by broth microdilution methods. Genes encoding carbapenemases including bla KPC , metallo-β-lactamase (MBL) genes, and bla OXA-48 were detected via multiplex PCR. Data retrieved from our 2012–2018 study were used for comparison. Of 3260 E. coli and 1457 K. pneumoniae isolates collected during 2020–2022, 0.9 % and 9.5 %, were INS-EC and INS-KP, respectively. Cefepime-zidebactam, ceftazidime-avibactam, imipenem-relebactam, and meropenem-vaborbactam were active against 100 %, 75.9 %, 65.5 %, and 79.3 % of 29 INS-EC isolates respectively; and against 100 %, 90.6 %, 64.5 %, and 67.4 % of 138 INS- KP isolates, respectively. Susceptibility was contingent upon carbapenemase types. Susceptibility rates of cefepime-zidebactam and ceftazidime-avibactam remained constant from 2012 to 2018 through 2020–2022 but those of imipenem-relebactam and meropenem-vaborbactam decreased significantly, which may be partially attributable to the increasing prevalence of bla OXA-48 . Eighteen MBL-gene-positive isolates and two bla KPC -positive isolates were resistant to ceftazidime-avibactam, whereas all were susceptible to cefepime-zidebactam. Tigecycline had a higher...